Moreover, the in-situ expression of CD101 was further analyzed using HPA databases based on IHC staining, in which CD101 expression remained the highest in high-grade glioma, followed by low-grade glioma and normal brain tissue, consistent with the results from transcriptional analyses (Figure 1C). The gene discussed is CD101; the disease is central nervous system cancer.